(888) 552-6760 SCHEDULE A CONSULTATION
Clinical-Trials

Clinical trials

Search our clinical trials

Cancer Treatment Centers of America® (CTCA) is committed to providing new and innovative treatments for our cancer patients whenever possible. This includes enrolling qualified patients in carefully selected clinical trials for cancer. Clinical trials are a key testing ground for determining the effectiveness and safety of new treatments and drugs for cancer and other diseases. Our doctors may recommend that cancer patients enroll in cancer clinical trials if they meet specific criteria. Cancer trials may offer patients access to treatment options that would otherwise be unavailable to them. Talk to your doctor about whether a cancer trial is a good option for you and ask about the risks and various requirements involved. Use the tool below to find a CTCA® clinical trial for your cancer type.

Filters

35 Clinical Trials

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This is a phase 2 multicenter, open-label study evaluating the efficacy, safety, tolerability, and pharmacokinetics (PK) of RMC-4630 in combination with sotorasib in subjects with KRASG12C mutant NSCLC after failure of prior standard therapies.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This is a phase 2, open-label, multi-center study to evaluate the efficacy and the safety/tolerability of poziotinib in seven patient cohorts for up to 603 previously treated and treatment-naïve NSCLC patients.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This phase II/III trial studies how well chemotherapy and radiation therapy (chemoradiation) with or without atezolizumab works in treating patients with limited stage small cell lung cancer.

   

Accepting new patients

 

Learn more at

clinicaltrials.gov

An open-label, phase 2 trial of nanatinostat in combination with valganciclovir in patients with Epstein-Barr virus-positive (EBV+) relapsed/refractory lymphomas.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone (Arm A) compared with that of combination of pomalidomide, bortezomib and dexamethasone (Arm B) in participants with relapsed/refractory multiple myeloma (RRMM).

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This is a randomized study of daratumumab plus lenalidomide vs. lenalidomide alone as maintenance treatment in patients with newly diagnosed multiple myeloma, who are minimal residual disease positive after frontline autologous stem cell transplant.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This study is a phase 1, open-label, multi-center dose escalation and dose expansion study in patients with relapsed or refractory multiple myeloma or non-Hodgkin lymphoma.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov
     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This phase 2 trial studies the possible benefits of treatment with different combinations of the drugs durvalumab, olaparib and cediranib vs. the usual treatment in patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back after a period of improvement with platinum therapy (recurrent platinum resistant).

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This phase 3 trial studies how well letrozole with or without paclitaxel and carboplatin works in treating patients with stage 2-4 low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum.